2013 Fiscal Year Final Research Report
Therapeutic drug management of tyrosine kinase inhibitor
| Project/Area Number |
23590168
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TAKAHASHI Naoto 秋田大学, 医学部, 講師 (80344753)
SATO Kazuhiro 秋田大学, 医学部, 講師 (30436191)
TSUCHIYA Norihiko 秋田大学, 医学部, 准教授 (70282176)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 分子標的抗がん剤 / TDM / 遺伝子多型 |
|---|
| Research Abstract |
Because of the variability in tyrosine kinase inhibitor(TKI) exposure among patients, therapeutic drug monitoring (TDM) to maintain a certain fixed plasma threshold level would be beneficial during TKI therapy. TDM service should be routinely provided to patients taking TKI. Patients at increased hyperbilirubinemia risk could be identified by prospective UGT1A1 genotyping prior to nilotinib therapy. The efficacy of the threshold plasma trough concentration of nilotinib should be set above 800 ng/mL for CML patients. Dasatinib efficacy and safety were associared with exposure (AUC). A lower dasatinib exposure was detected among patients with T315I compared to those without the mutation. These data suggest that sufficient exposure of dasatinib may prohibit clonal evolution by adequately inhibiting BCR-ABL kinase. And plasma trough concentration of dasatinib should not exceed 2.5 ng/mL in CML patients.
|
